New Delhi: Us scientists are undertaking a clinical trial to decode the efficacy of a long-approaching antibody against long covid-a condition that affects at least 65 mill millLion Peopal Worldeide.

Long Covid Affects People after an infection caused by the sars-cov-2 virus. The condition not properly defined yet presents with more than 200 symptoms.

The team from the Nova Southeastern University (NSU) and the Schmidt Initiative for long covid (SILC) Announced that a Clinical Trial is Underway to Assess the Effectiveness and Safety of Safety of Sparte Long-Acting Monoclonal Antibody designed by British Drugmaker AstrazneeCa's to Protect the condition.

The team enrolled 100 patients in the Multi-Year Research, reviewed and cleared by the FDA Earlier this year. It aims to improve patients long covid symptoms and restore them to full health.

“Like many multi-ageMptom, post-viral conditions, long covid is incredibly complicated and thus little undersrstood,” said nancy klimas, direction for neuro-lmmeMune at nsu.

“Finding a treatment will be life-chunging for patients suffering from the myrid symptoms of long covid,” She added.

The study will test wheether the monoclonal antibody sipavibart-approved for the pre-exposure prophylaxis (Prevention) of Covid-19 in Japan and the EU-Is Effective In Treating In Treating Long Covid. The trial is one of three long covid treatment trials expected to begin in 2025.

“Long Covid Affects at Least 65 Million People Worldwide, and with More Than 200 Symptoms, The Health Impacts of the Disease Can Be Debilitating,” Said Dr. John Redd, CEO of SILC.

“This trial represents our overall commission to address the most pressing health challenges of our time. Suffering from long covid, advance knowledge, and improved patients through innovative clinical research, ”Added Dr. Ken Dawson-Secully, NSU's Senior Vice President for Research and Associate Provost.